Therapy News and Research

RSS

Enrolment complete in Veloxis LCP-Tacro Phase III study in de novo kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.

29 Mar 2012

COPD Foundation to lead DRIVE4COPD campaign

The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.

29 Mar 2012

Elekta receives EU CE marking for Connexion modular couchtop

Elekta's Connexion modular couchtop is CE marked and successfully released for sale in the European Union. Connexion meets the clinic's need to tailor patient set-up to accommodate the unique therapy requirements of the individual patient.

From Elekta 29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

VasoStitch percutaneous access-and-closure system featured at ACC annual meeting

VasoStitch is developing a percutaneous access-and-closure system for the nonsurgical deployment of large-diameter transcatheter therapeutic devices, such as Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm Repair (EVAR) devices. The VasoStitch system is designed to reduce procedural complexity and eliminate the need for an "open" surgical procedure.

29 Mar 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Depression more prevalent among stroke and transient ischemic attack survivors

Depression is more prevalent among stroke and transient ischemic attack survivors than in the general population, researchers reported in the American Heart Association's journal Stroke.

29 Mar 2012

Study explores relationship between traumatic early life events and gynecological cancer

An investigation that is published in the current issue of Psychotherapy and Psychosomatics explores the relationship between early life events and gynecological cancer.

29 Mar 2012

EMA grants orphan designations to Ultragenyx UX001, UX003 for treatment of HIBM and MPS 7

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.

29 Mar 2012

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data.

29 Mar 2012

Gene therapy improves chylomicron metabolism in LPLD patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.

29 Mar 2012

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

Amerigroup announces successful efforts at preventing premature births

Amerigroup Corporation announced its successful efforts at preventing premature births – as well its commitment to protecting access to affordable drug therapies for at-risk mothers – at the annual Norfolk/Virginia Beach March of Dimes kick-off breakfast for the March for Babies.

29 Mar 2012

IMRT associated with reduced toxicities when compared with standard whole breast irradiation

Breast cancer patients treated with intensity modulated radiation therapy (IMRT) instead of standard whole breast irradiation (WBI) have a lower incidence of acute or chronic toxicities, according to a study in Practical Radiation Oncology (PRO), the official clinical practice journal of the American Society for Radiation Oncology (ASTRO).

29 Mar 2012

Researchers profile genetic changes in cancer with drug sensitivity

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.

29 Mar 2012

Spherix 2011 net loss decreases to $3.5 million

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2011, and recent and upcoming business highlights.

29 Mar 2012

Relievant Medsystems secures $30M in Series D equity financing

Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.

29 Mar 2012

Chromosomal abnormality in children with ependymoma linked with poorer chance of survival

A chromosomal abnormality in children with a deadly form of brain cancer is linked with a poorer chance of survival, clinician scientists at The University of Nottingham have discovered.

29 Mar 2012

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.

29 Mar 2012

Inhibitory control test and lactulose for MHE saves more than $3 million over 5 years

A late stage liver condition, known as minimal hepatic encephalopathy (MHE), is associated with impaired driving skills and greater risk of motor vehicle accidents. Cost analysis of management strategies for detection and treatment of MHE are published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2012

Therapy News and Research

Enrolment complete in Veloxis LCP-Tacro Phase III study in de novo kidney transplant patients

COPD Foundation to lead DRIVE4COPD campaign

Elekta receives EU CE marking for Connexion modular couchtop

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

VasoStitch percutaneous access-and-closure system featured at ACC annual meeting

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

Depression more prevalent among stroke and transient ischemic attack survivors

Study explores relationship between traumatic early life events and gynecological cancer

EMA grants orphan designations to Ultragenyx UX001, UX003 for treatment of HIBM and MPS 7

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Gene therapy improves chylomicron metabolism in LPLD patients

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Amerigroup announces successful efforts at preventing premature births

IMRT associated with reduced toxicities when compared with standard whole breast irradiation

Researchers profile genetic changes in cancer with drug sensitivity

Spherix 2011 net loss decreases to $3.5 million

Relievant Medsystems secures $30M in Series D equity financing

Chromosomal abnormality in children with ependymoma linked with poorer chance of survival

Clovis commences CO-1686 Phase I/II study in NSCLC

Inhibitory control test and lactulose for MHE saves more than $3 million over 5 years

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News